Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Antimicrobial Agents and Chemotherapy
Cirle A WarrenPaul S Hoffman

Abstract

Clostridium difficile infection (CDI) is a serious diarrheal disease that often develops following prior antibiotic usage. One of the major problems with current therapies (oral vancomycin and metronidazole) is the high rate of recurrence. Nitazoxanide (NTZ), an inhibitor of pyruvate:ferredoxin oxidoreductase (PFOR) in anaerobic bacteria, parasites, Helicobacter pylori, and Campylobacter jejuni, also shows clinical efficacy against CDI. From a library of ∼250 analogues of NTZ, we identified leads with increased potency for PFOR. MIC screens indicated in vitro activity in the 0.05- to 2-μg/ml range against C. difficile. To improve solubility, we replaced the 2-acetoxy group with propylamine, producing amixicile, a soluble (10 mg/ml), nontoxic (cell-based assay) lead that produced no adverse effects in mice by oral or intraperitoneal (i.p.) routes at 200 mg/kg of body weight/day. In initial efficacy testing in mice treated (20 mg/kg/day, 5 days each) 1 day after receiving a lethal inoculum of C. difficile, amixicile showed slightly less protection than did vancomycin by day 5. However, in an optimized CDI model, amixicile showed equivalence to vancomycin and fidaxomicin at day 5 and there was significantly greater survival produc...Continue Reading

References

Jan 27, 1994·The New England Journal of Medicine·C P KellyJ T LaMont
Sep 18, 1999·Acta Crystallographica. Section D, Biological Crystallography·E ChabrièreM H Charon
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·C S McVay, R D Rolfe
Jun 11, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Usha StiefelCurtis J Donskey
Apr 26, 2006·Expert Opinion on Pharmacotherapy·Andrew HemphillMarco Esposito
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fred A ZarMelinda B Davis
Feb 7, 2008·Emerging Infectious Diseases·Matthew D RedelingsLaurene Mascola
May 30, 2008·Emerging Infectious Diseases·Marya D ZilberbergMarin H Kollef
Oct 14, 2008·Gastroenterology·Xinhua ChenCiarán P Kelly
Jan 13, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel M MusherJean-François Rossignol
Sep 10, 2009·Journal of Medicinal Chemistry·Luiz Pedro S de CarvalhoCarl Nathan
Apr 21, 2010·Antimicrobial Agents and Chemotherapy·Florence Tchouaffi-NanaPaul S Hoffman
May 7, 2010·Journal of Veterinary Pharmacology and Therapeutics·Z ZhaoX Meng
May 22, 2010·Bioorganic & Medicinal Chemistry Letters·T Eric BallardTimothy L Macdonald
Oct 28, 2010·The Journal of Infectious Diseases·S W PawlowskiR L Guerrant
Dec 1, 2010·Pharmacotherapy·Charles VenutoJack Brown
Feb 4, 2011·The New England Journal of Medicine·Thomas J LouieUNKNOWN OPT-80-003 Clinical Study Group
May 18, 2011·Infection and Immunity·Xingmin SunHanping Feng
Jun 21, 2011·Annual Review of Microbiology·Karen C Carroll, John G Bartlett
Jul 20, 2011·Surgical Infections·Christine S Cocanour
Aug 4, 2011·Expert Review of Anti-infective Therapy·Kathleen M Mullane, Sherwood Gorbach
Aug 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kathleen M MullaneSherwood L Gorbach

❮ Previous
Next ❯

Citations

Jun 19, 2013·The Journal of Infectious Diseases·Erica L BuonomoWilliam A Petri
Oct 8, 2014·Pharmaceutical Patent Analyst·Sukhbir K Shahid
Dec 3, 2016·Infectious Diseases and Therapy·Csaba FehérJosep Mensa
Feb 18, 2017·Trends in Pharmacological Sciences·Benjamin K Johnson, Robert B Abramovitch
Jan 30, 2016·Antimicrobial Agents and Chemotherapy·Peter ChahalesDavid G Thanassi
Oct 30, 2013·Infection and Immunity·Rajat MadanWilliam A Petri
Oct 10, 2018·Antimicrobial Agents and Chemotherapy·Luther A BarteltPaul S Hoffman
Apr 17, 2019·Antimicrobial Agents and Chemotherapy·T J De WolfeN Safdar
Aug 29, 2013·Current Opinion in Infectious Diseases·Alaina S Ritter, William A Petri
Oct 28, 2017·The Journal of Antimicrobial Chemotherapy·Simon A Dingsdag, Neil Hunter
May 2, 2020·Antibiotics·Paul S Hoffman
Sep 7, 2017·Scientific Reports·Justin A HutchersonJanina P Lewis
Nov 11, 2019·Journal of Oral Biosciences·Qin GuiJanina P Lewis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.